Canaccord Genuity Maintains Buy on Tango Therapeutics, Raises Price Target to $46
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst John Newman maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $42 to $46.
Canaccord Genuity analyst John Newman maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $42 to $46.